2025 Annual Meeting | H180 - Acceleration Through Collaboration in Neurodegenerative Diseases (Innovation Hub)

Date Tuesday 04/08/25

Time 02:50 PM - 03:20 PM PDT Add To Calendar

Location San Diego Convention Center | Exhibit Hall BCD

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Hubs (Innovation)

Director(s) Jinsy Andrews, MD, FAAN

Moderator(s) Andrea Goodman

Topic(s) General Neurology

Learning Objectives This insightful panel discussion will explore the transformative power of collaboration in the fight against neurodegenerative diseases. In this session, experts from across the neurodegenerative field will delve into how increased coordination among researchers, clinicians, advocacy groups, patients and policymakers can foster greater public awareness and accelerate groundbreaking scientific discoveries. This session will inspire, inform, and motivate individuals to think differently about the power of collaboration in advancing both science and patient care. Join us to learn how we can all play a role in enhancing the quality of life for those affected by neurodegenerative diseases.

CME Available No CME available

Core Competencies Systems-based Practice, Quality Improvement

Program Level Intermediate

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider, Neurohospitalist, Medical Student, Coordinator

Teaching Styles Other

Program Materials Program Evaluations

Event Timeline
02:50 PM - 03:20 PM PDT	Speaker	Acceleration Through Collaboration in Neurodegenerative Diseases. Jinsy Andrews, MD, FAAN

Faculty Disclosures
Jinsy Andrews, MD, FAAN	Dr. Andrews has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Andrews has received personal compensation in the range of $0-$499 for serving as a Consultant for Cytokinetics. Dr. Andrews has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amylyx. Dr. Andrews has received personal compensation in the range of $0-$499 for serving as a Consultant for Regeneron. Dr. Andrews has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AL-S Pharma. Dr. Andrews has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Andrews has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Quralis . Dr. Andrews has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for Neurosense. Dr. Andrews has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Akava. The institution of Dr. Andrews has received research support from Amylyx. The institution of Dr. Andrews has received research support from Biogen . The institution of Dr. Andrews has received research support from Cytokinetics . The institution of Dr. Andrews has received research support from NIH . The institution of Dr. Andrews has received research support from Prilenia/Platform Trial . The institution of Dr. Andrews has received research support from Calico/Platform Trial . The institution of Dr. Andrews has received research support from Corcept.
Andrea Goodman	No disclosure on file
Peggy Plews-Ogan, MD	No disclosure on file
Wanda Smith	No disclosure on file

��ɫ��

��ɫ��